

Geor Bakker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5266931/publications.pdf>

Version: 2024-02-01

14
papers

615
citations

933447

10
h-index

1125743

13
g-index

15
all docs

15
docs citations

15
times ranked

1892
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of copy number variations on brain structure and risk for psychiatric illness: Large-scale studies from the ENIGMA working groups on CNVs. Human Brain Mapping, 2022, 43, 300-328.	3.6	30
2	Virtual Histology of Cortical Thickness and Shared Neurobiology in 6 Psychiatric Disorders. JAMA Psychiatry, 2021, 78, 47.	11.0	136
3	Large-scale mapping of cortical alterations in 22q11.2 deletion syndrome: Convergence with idiopathic psychosis and effects of deletion size. Molecular Psychiatry, 2020, 25, 1822-1834.	7.9	122
4	Altered white matter microstructure in 22q11.2 deletion syndrome: a multisite diffusion tensor imaging study. Molecular Psychiatry, 2020, 25, 2818-2831.	7.9	50
5	The muscarinic M1 receptor modulates associative learning and memory in psychotic disorders. NeuroImage: Clinical, 2020, 27, 102278.	2.7	7
6	Increased power by harmonizing structural MRI site differences with the ComBat batch adjustment method in ENIGMA. NeuroImage, 2020, 218, 116956.	4.2	135
7	MATLAB doesn't love me: an essay. , 2020, , .		1
8	Influence of muscarinic M1 receptor antagonism on brain choline levels and functional connectivity in medication-free subjects with psychosis: A placebo controlled, cross-over study. Psychiatry Research - Neuroimaging, 2019, 290, 5-13.	1.8	7
9	Relationship between muscarinic M1 receptor binding and cognition in medication-free subjects with psychosis. NeuroImage: Clinical, 2018, 18, 713-719.	2.7	26
10	Dopamine in high-risk populations: A comparison of subjects with 22q11.2 deletion syndrome and subjects at ultra high-risk for psychosis. Psychiatry Research - Neuroimaging, 2018, 272, 65-70.	1.8	6
11	The effect of the muscarinic M 1 receptor antagonist biperiden on cognition in medication free subjects with psychosis. European Neuropsychopharmacology, 2017, 27, 854-864.	0.7	15
12	Cortical Morphology Differences in Subjects at Increased Vulnerability for Developing a Psychotic Disorder: A Comparison between Subjects with Ultra-High Risk and 22q11.2 Deletion Syndrome. PLoS ONE, 2016, 11, e0159928.	2.5	23
13	¹²³ I-Iododexetimide Preferentially Binds to the Muscarinic Receptor Subtype M ₁ In Vivo. Journal of Nuclear Medicine, 2015, 56, 317-322.	5.0	22
14	Pharmacological Interventions for the MATRICS Cognitive Domains in Schizophrenia: What's the Evidence?. Frontiers in Psychiatry, 2013, 4, 157.	2.6	35